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system in conventional glucose peritoneal dialysis fluid
REIKO INAGI, TOSHIO MIYATA, YASUHIKO UEDA, ATSUSHI YOSHINO, MASAOMI NANGAKU,
CHARLES VAN YPERSELE DE STRIHOU, and KIYOSHI KUROKAWA
Molecular and Cellular Nephrology, Institute of Medical Sciences and Department of Medicine, Tokai University School of
Medicine, Kanagawa, Japan, and Service de Nephrologie, Universite Catholique de Louvain, Brussels, Belgium
stress in PD patients. The clinical relevance of this approachEfficient in vitro lowering of carbonyl stress by the glyoxalase
is yet to be documented.system in conventional glucose peritoneal dialysis fluid.
Background. Reactive carbonyl compounds (RCOs) pres-
ent in heat-sterilized peritoneal dialysis (PD) fluid have been
incriminated in the progressive deterioration of the peritoneal The quality of the peritoneal membrane deterioratesmembrane observed in long-term PD patients. The present
progressively with peritoneal dialysis (PD) duration, atstudy utilized the glyoxalase I (GLO I) system as a new ap-
least in part as a consequence of the PD fluid glucoseproach to lower in vitro the peritoneal fluid content of RCOs
such as methylglyoxal (MGO), glyoxal (GO) and 3-deoxyglu- content [1, 2]. Glucose is known to degrade into several
cosone (3-DG). reactive carbonyl compounds (RCOs) during heat steril-
Methods. GO, MGO, and 3-DG solutions or conventional ization, such as glyoxal (GO), methylglyoxal (MGO) andglucose PD fluids were incubated in vitro with various RCO
3-deoxyglucosone (3-DG), all of which may alter thelowering compounds. The evolution of GO, MGO, and 3-DG
peritoneal membrane [3–5]. First, they contribute to thelevels was monitored by high-performance liquid chromatogra-
phy. The tested compounds included aminoguanidine and glu- advanced glycation of proteins with the eventual accu-
tathione (GSH), alone or together with GLO I. The human mulation of advanced glycation end products (AGEs)
GLO I gene was overexpressed in Chinese hamster ovary in the mesothelial layers and in the wall of peritoneal
(CHO) cells, or ubiquitously in transgenic mice. Cell superna-
vessels [6–8]. AGEs, such as Nε-carboxymethyllysinetant of the CHO transfectant and protein extracts of various
(CML) and pentosidine, colocalize in the endotheliumorgans of the transgenic mice were also tested.
Results. Aminoguanidine incubated with MGO/GO/3-DG of peritoneal vessels with the vascular endothelial growth
mixtures, promptly reduced RCO levels. GSH alone had a factor (VEGF) [9, 10]. Second, the in vitro exposure
similar but milder and slower effect. Together with GLO I, it of cultured mesothelial and endothelial cells to MGO
promptly decreased GO and MGO levels but was less efficient increases mRNA and protein synthesis of VEGF [9].toward 3-DG. After incubation with glucose PD fluid, GSH
Repeated in vivo intraperitoneal loads of MGO alsotogether with GLO I had the same effect on MGO, GO, and
raise VEGF expression in rat peritoneal tissue [9]. Alto-3-DG levels. Addition of transfected cell supernatant or tissue
extracts overexpressing GLO I, together with GSH to either gether, these findings suggest that intraperitoneal RCOs,
GO, MGO, or 3-DG solutions, promptly and markedly reduced at least transiently, contribute to the production and
GO and MGO but not 3-DG levels. release of VEGF, a potent factor enhancing vasodilation,
Conclusions. GLO I together with GSH efficiently lowers
vascular permeability, nitric oxide synthase productionglucose-derived RCOs, especially GO and MGO, both in con-
and eventually angiogenesis, and thus contribute to ultra-ventional glucose PD fluids and in RCO solutions. The fact
that genetically manipulated cells overexpressing GLO I activ- filtration failure. Furthermore, glucose degradation RCOs
ity have a similar effect suggests that maneuvers raising GLO I inhibit cell growth, viability, and inflammatory cytokines
activity in peritoneal cells or in the peritoneal cavity might release of cultured mesothelial cells [11].
help prevent the deleterious effects of the peritoneal carbonyl
Therefore, strategies have been designed to decrease
RCOs in PD fluids. We previously reported the beneficial
effects on PD fluid RCO levels of the newer glucose freeKey words: reactive carbonyl compound, glyoxalase, glutathione, peri-
toneal dialysis, advanced glycation end product. PD fluids [12], that is, icodextrin and amino acids, or
of inhibitors of carbonyl amine chemistry [13], that is,
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crue from manipulations of the glyoxalase pathway. This analyzed by reverse-phase high-performance liquid chro-
matography (HPLC) [7] using a Waters Purecil C18 col-pathway detoxifies some RCOs [14]: it entails reversible
binding of MGO and GO with the thiol group of glutathi- umn (5 m, 4.6  250 mm). Detection was carried out
spectrophotometrically at an absorption wavelength ofone (GSH) and its eventual metabolization by glyoxalase
(GLO) I and II into d-lactate and GSH. Overexpression 315 nm. The linear gradient elution (solvent A:solvent
B ratio) used in this study was 85:15 to 70:30 in 25 minutesof GLO I in endothelial cells has been shown to inhibit
glucose driven intracellular AGE formation [15]. Our with solvent A containing 0.1% trifluoroacetic acid and
solvent B comprised of 80% acetonitrile and 0.08% tri-results demonstrate that this approach indeed improves
PD fluid biocompatibility. fluoroacetic acid.
GLO I transfection
METHODS
Human GLO I cDNA, kindly provided by Dr. S. Kato,
GLO I activity (Sagami Chemical research Center, Kanagawa, Japan)
was cloned into the EcoR I site of the pcDNA 3.1/myc-Glyoxalase I was assayed by spectrophotometry ac-
cording to the method by McLellan and Thornalley [16], His B vector (Invitrogen, Carsbad, CA, USA) with a
Takara Ligation Kit Ver 2.0 (Tokyo, Japan). The vectormonitoring the increase in absorbance at 240 nm due to
the formation of S-d-lactoylglutathione for two minutes inserted with GLO I cDNA was transfected into CHO
cells by lipofection using a kit (Lipofectamine Plus;at 25C.
Gibco BRL, Gaithersburg, MD, USA) and cultured in
In vitro incubation experiment Dulbecco’s modified Eagle’s medium (DMEM; Nissui
Pharmaceutical, Tokyo, Japan) supplemented with 10%Commercial heat-sterilized PD solution containing
glucose (1.36% glucose; Dianeal PD-4) was obtained fetal bovine serum (FBS).
The culture medium obtained 24 hours after transfec-from Baxter Healthcare Corporation (Round Lake, IL,
USA). MGO and yeast GLO I purified to homogeneity tion from the transfectant cells, at confluency was centri-
fuged at 20,000  g for 20 minutes at 4C. The cellwere obtained from Sigma Chemical Co. (St. Louis, MO,
USA) and GO from Wako Pure Chemicals (Osaka, Ja- supernatant was utilized to assess GLO I activity and
RCO reduction.pan). 3-DG was prepared according to the method of
Kato et al [17].
GLO I transgenic miceA solution of GO, MGO, and 3-DG (200 M each)
was incubated with or without 3 mmol/L aminoguanidine To generate the human GLO I transgene construct,
entire coding sequence of human GLO I cDNA was(Tokyo Chemical Industry, Tokyo, Japan) or 3 mmol/L
GSH (Wako Pure Chemicals) in 0.1 mol/L sodium phos- cloned into the EcoR I site of the pBsCAG-2. The GLO I
transgene isolated by digestion of pBsCAG-2 containingphate buffer (NaPB), pH 7.4, at 37C. The GO, MGO,
and 3-DG contents of the incubation mixtures were de- GLO I cDNA with Kpn I and Sac I was microinjected
into one pronucleus of fertilized C57BL/6 eggs, followedtermined after 0, 1, 5, or 24 hours of incubation as de-
scribed below. by transfer into the oviducts of pseudopregnant mice as
described elsewhere. Mouse genomic DNA extractedIn some experiments, solutions containing either GO
or MGO, or 3-DG (100 mol/L) in NaPB, pH 7.4, or from tail tissue was used to detect the transgene by poly-
merase chain reaction (PCR) using specific primers forconventional 1.36% glucose PD fluid, pH 5.5, were incu-
bated with various concentrations of GSH and GLO I GLO I or pBsCAG-2 vector. Primers for cytomegalovi-
rus enhancer (Pr1 in Fig. 5), sense (5-GTC GAC ATTat 37C for one hour. In addition, solutions containing
either GO or MGO or 3-DG (100 mol/L) were incu- GAT TAT TGA CTA G-3) and antisense (5-CCA
TAA GGT CAT GTA CTG-3), amplified a 250 bpbated for one hour with the culture supernatant of hu-
man GLO I transfected Chinese hamster ovary (CHO) fragment. Primers for the fragment containing human
GLO I gene and 3 junction of vector (Pr2), sense (5-cells or tissue lysates from human GLO transgenic mice
together with various GSH solutions. GTA GTG TGG GTG ACT CCT CCG TTC CTT
GGG-3) and antisense (5-TCG AGG GAT CTT CATAt the end of each of these hour-long incubations, the
contents of GO, MGO, or 3-DG were determined by AAG AGA AGA G-3), amplified a 1200 bp fragment.
PCR amplification was carried out with an initial dena-HPLC as described below.
ture at 94C for two minutes, followed by 25 cycles of
HPLC analysis of GO, MGO and 3-DG 94C for 30 seconds, 55C for 30 seconds, and 72C for
one minute.The incubation mixture was incubated with 50 mol/L
2,3-butanedione (as an internal standard), 2 mol/L per- Animals were treated in accordance with the guide-
lines of the Committee on Ethical Animal Care and Use.chloric acid and 1% o-phenylenediamine. After incuba-
tion at 25C for three hours, quinoxaline derivatives were Mice were placed in metabolic cages with free access to
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Fig. 1. Change in glyoxal (GO), methylgly-
oxal (MGO) and 3-deoxyglucosone (3-DG)
levels induced by aminoguanidine (A ) and
glutathione (GSH) (B ). The reactive carbonyl
compounds (RCOs) mixture containing GO,
MGO, and 3-DG (200 mol/L each) was incu-
bated at 37C with 3 mmol/L aminoguanidine
or 3 mmol/L GSH in sodium phosphate buffer
(NaPB) pH 7.4. After 0, 1, 5, or 24 hour, the
GO, MGO, and 3-DG contents in the incubate
were determined by HPLC. Reaction mix-
tures without aminoguanidine or GSH and
without incubation were used as controls.
Data are expressed as percentage of each con-
trol and represent the mean  SD of three
independent experiments. *P  0.05 vs. con-
trol, **P  0.001 vs. control.
water. A 24-hour urine collection to evaluate proteinuria luted alkaline phosphatase conjugated goat anti-rabbit
IgG (Cappel Laboratory, Durham, NC, USA) and devel-was obtained one day before sacrifice by cervical disloca-
oped with a p-nitro blue tetrazolium chloride and 5-bro-tion. Blood samples were collected at the time of sacrifice
mo-4-chloro-3-indolyl-phosphate solution (Bio Rad Lab-for hematological and biochemical analyses. Samples
oratories). We used 10% red blood cell suspension asfrom various organs were fixed in 4% neutral buffered
control and anti-actin antibody (affinity isolated antigenformaldehyde, embedded in paraffin, and sectioned at
specific, Sigma) for normalization.4 m thickness, followed by hematoxylin and eosin
(H&E) or the periodic-acid Schiff (PAS) staining for
Statistical analysislight microscopic analysis.
Tissues (50 mg) from wild or heterozygous GLO I Statistical differences were tested using the Student
t test. A P value of less than 0.05 was considered statisti-transgenic F1 mice were homogenized in 1 mL of NaPB,
pH 7.0, containing 0.02% TritonX-100 and centrifuged cally significant. Data are expressed as the mean  SD.
at 20,000 g for 20 minutes at 4C. The supernatant was
used as a tissue lysate to assess GLO I by immunoblot
RESULTSanalysis, GLO I activity and RCO reduction.
Effects of aminoguanidine and of GSH on
Immunoblotting RCO reduction
A 10 L sample of proteins extracted from tissues Addition of aminoguanidine to the solution containing
was denatured by boiling for five minutes, separated by GO, MGO and 3-DG, reduced their levels very rapidly
sodium dodecyl sulfate-polyacrylamide gel electrophore- over a 24 hour period (Fig. 1A), in good agreement with
sis (SDS-PAGE) on an acrylamide gradient gel (4 to previous findings [13].
20%), and electrophoretically transferred to a polyvinyli- Addition of GSH to the GO/MGO/3-DG mixtures
dene difluoride (PVDF) membrane (Bio-Rad Labora- also decreased GO and MGO levels, but was less efficient
tories, Hercules, CA, USA). The membrane was blocked for 3-DG. The effect was much slower than that of
overnight at 4C with phosphate-buffered saline (PBS) aminoguanidine. GO and MGO disappeared completely
containing 0.05% Tween 20 and 2% bovine serum albu- after 5 and 24 hours, respectively, whereas 3-DG de-
min (BSA), and incubated with rabbit anti-human GLO I creased mildly after 24 hours only (Fig. 1B).
IgG (1 g/mL), kindly provided by Dr. S. Ranganathan,
Effects of yeast GLO I on RCOs reduction(Department of Pharmacology, Fox Chase Cancer Cen-
ter, USA) [18]. The membrane was washed with PBS Glutathione is undoubtedly less toxic than aminogua-
nidine and should be better tolerated to reduce glucose-containing 0.05% Tween 20, incubated with 1:5000 di-
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derived RCOs. It is however less efficient. Fortunately,
its effect is markedly improved by the addition of GLO I
(Fig. 2). The simultaneous addition of various concentra-
tions of GLO I and GSH lowered GO, MGO and 3-DG
to a much greater extent and within a much shorter
period of incubation than in the absence of GLO I. After
a one hour incubation, GO was lowered around 40% of
its initial value in the presence of various combinations
of GSH and GLO I concentrations (GSH 10 mmol/L 
GLO I 0.01 or 0.1 U/mL) and virtually suppressed
(5%) at higher concentrations (GSH 10 mmol/L 
GLO I 1 or 10 U/mL or GSH 1 mmol/L  GLO I
10 U/mL). Similar effects were noted for MGO, full
suppression being observed (GSH 1 or 10 mmol/L with
GLO I 1 or 10 U/mL and for GSH 0.1 mmol/L and
GLO I 10 U/mL). Reduction of 3-DG to less than 60%
was observed only for higher concentrations (GSH 1 or
10 mmol/L with GLO I 10 U/mL).
Conventional glucose (1.36%) PD fluid contained GO
4.2 mol/L, MGO 4.8 mol/L and 3-DG 64.7 mol/L.
The addition of both GLO I and GSH to conventional
glucose PD fluid decreased GO, MGO and 3-DG levels
(Fig. 3). After a one hour incubation, GO and MGO
levels fell by over 90% in the presence of GSH 1 or 5
mmol/L together with GLO I 1 or 5 U/mL. Reduction
of 3-DG was less striking: over 20% in the presence of
GSH 5 mmol/L with GLO I 1 or 5 U/mL, or of GSH 1
mmol/L with GLO I 5 U/mL. The levels of RCOs in PD
fluid were significantly lower with both GSH 5 mmol/L
and GLO I 1 U/mL (GO 0.22 mol/L; MGO 0.54
mol/L; 3-DG 48.1 mol/L) than with GSH alone (GO
3.6 mol/L; MGO 4.2 mol/L; 3-DG 62.2 mol/L).
Effects of human GLO I overexpression on
RCOs reduction
In our previous experiments chemically pure yeast
GLO I was used. We subsequently tried to raise the
activity of human GLO I in peritoneal cells with the
intent to reduce the peritoneal carbonyl stress derived
from PD fluids. First, GLO I was overexpressed in CHO
cells and the effects of GLO I on RCO levels of either
GO or MGO, or 3-DG solutions were investigated in
vitro. CHO cells were chosen because they are easier to
transfect and provide more stable data as compared to
primary cultured mesothelial and/or endothelial cells.
GLO I activity was up-regulated by transfection of hu-
man GLO I cDNA into CHO cells by lipofection. The
GLO I activity was significantly higher (P  0.001) in
GLO I-transfected CHO cells as compared to the mock-
Fig. 2. Change in GO (A), MGO (B), and 3-DG (C ) levels induced transfected CHO cells both in the culture supernatant
by GLO I and GSH. A solution containing 100 mol/L of either GO
or MGO or 3-DG in NaPB, pH 7.4, was incubated for one hour at 37C
with various concentrations of GSH (0, 0.1, 1, 10 mmol/L) and GLO I
(0, 0.01, 0.1, 1 and 10 U/mL). GO, MGO, and 3-DG contents were then
determined by HPLC. Reaction mixtures without GSH and GLO I,
and without incubation were used as controls. Data are expressed as independent experiments. *P  0.05 vs. control, #P  0.01 vs. the
the percentage of each control and represent the mean  SD of three control, **P  0.001 vs. control.
Inagi et al: Glyoxalase system lowers carbonyl stress 683
(2.53  0.30 U/mL vs. 0.01  0.002 U/mL) and in the
cell lysate (11.75  1.25 U/105 cells vs. 0.64  0.18 U/105
cells). When GO, MGO, or 3-DG was incubated together
with GSH and the culture supernatant from GLO I
transfectant or mock transfectant, the level of GO and
MGO but not 3-DG (data not shown) was significantly
lower after one hour in the culture supernatant of GLO I
transfectant than those in the mock transfectant (Fig.
4). The effect required the presence of GSH and was
enhanced by increasing GSH concentrations.
Subsequently we generated human GLO I transgenic
mice. The full-length GLO I cDNA was overexpressed
under control of the cytomegalovirus enhancer/chicken
-actin promoter system (Fig. 5A). Of 96 putative found-
ers, 15 had GLO I transgene detected by PCR analysis
of the genomic DNA. Two of the 15 transgenic founders
were successfully bred to C57BL/6 mice and two inde-
pendent lines (lines A and B) were established. Both
lines had 250 bp (Pr1 in Fig. 5) and 1200 bp (Pr2) frag-
ments of GLO I transgene by PCR analysis (data not
shown). By Southern blot analysis of mouse genomic
DNA, each lineage had a distinct integration pattern.
Both lines transmitted the transgene to their progeny
and litter sizes were comparable to controls, suggesting
normal reproductive behavior. Hematological and bio-
chemical analyses of blood samples of transgenic (N 	
5) or wild-type (N	 4) mice demonstrated that the levels
of red and white blood cells, platelets, plasma glucose,
BUN and creatinine and the urinary protein concentra-
tion were not significantly different between the two
groups at 10 weeks after birth. Histological examinations
of kidney, liver, heart, lung, spleen, brain, pancreas, in-
testine, and testis also revealed no abnormality in the
transgenic mice.
The up-regulated protein expression of human GLO I
gene products (approximately 24 kD) in the transgenic
mice was confirmed by immunoblot analysis of crude
tissue homogenates utilizing anti-GLO I antibody (Fig.
5B). Kidney and heart tissue extracts from human GLO I
transgenic mice contained significantly higher levels of
GLO I than those from wild-type mice. Protein expres-
sion of GLO I was augmented in all examined tissues
of transgenic mice.
The GLO I activities in protein extracts of heart, liver,
and kidney, but not red blood cells and plasma, from two
lines of human GLO I transgenic mice were significantly
higher than those in protein extracts from wild-type mice
(Table 1). Incubation of the protein extracts of heartFig. 3. Change in GO (A ), MGO (B ), and 3-DG (C ) levels in conven-
from GLO I transgenic mice (line A) with either GO ortional PD fluid induced by GLO I and GSH. Conventional glucose PD
fluid (1.36%, pH 5.5) was incubated for one hour at 37C with various MGO or 3-DG solutions dramatically lowered only GO
concentrations of GSH (0, 1 and 5 mmol/L) and GLO I (0, 1 and 5 and MGO levels to a much greater extent than thoseU/mL). The GO, MGO, and 3-DG contents were then determined
from wild-type mice (Fig. 6). The effect required theby HPLC. Reaction mixtures without GSH and GLO I, and without
incubation were used as controls. Data are expressed as percentage presence of GSH and was enhanced by increasing GSH
of each control and represent the mean  SD of three independent concentrations. Similar results were observed with pro-experiments. *P  0.05 vs. control, **P  0.001 vs. control.
tein extracts of other organs including kidney from the
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tion with tissue lysate of heart from wild-type mice (GO
73.9mol/L; MGO 24.9 mol/L) in the presence of GSH
0.4 mmol/L.
DISCUSSION
Several approaches have been tested to reduce the
carbonyl content of peritoneal dialysate: suppression of
glucose as in icodextrin or amino acid PD fluid [19–21],
or double bag systems in which glucose is heat sterilized
at a low pH with an attendant reduction of RCO produc-
tion [22, 23], and the addition of drugs such as aminogua-
nidine or OPB-9195 capable of trapping reactive carbon-
yls [13]. The present study relied on a more physiological
approach to degrade reactive carbonyls, the glyoxalase
pathway. We demonstrate in vitro that, together with
GSH, GLO I reduces the levels of GO, MGO and to a
small extent 3-DG, when dissolved in NaPB or present
in standard 1.36% glucose dialysate. Of further interest,
the supernatant of cells genetically manipulated to over-
express GLO I or tissue lysate of transgenic animals
overexpressing GLO I have a similar effect on MGO
and, to a smaller extent, on GO levels.
This physiologic approach stands in contrast with the
benefits of drugs able to trap reactive carbonyls. Amino-
guanidine and OPB-9195 reduce the levels of GO, MGO
and 3-DG with a similar efficiency. Unfortunately, their
ability to bind various other substances, such as vitamin
B6 [24] with an eventual vitamin B6 deficiency, sharply
limits their use. The effect of GLO I requires the pres-
ence of GSH, an intermediate molecule that binds RCOs
and then undergoes a metabolization restoring GSH lev-
els while transforming the RCO into d-lactate. GLO I
activity in peritoneal dialysate is rate limiting: the higher
the concentration of GLO I in glucose PD fluid the
more profound the decrease of RCOs level. The same
phenomenon is observed in GO or MGO solutions. In-
terestingly, at each level of GLO I activity, the RCO
Fig. 4. Change in GO (A), and MGO (B) levels in the culture medium lowering effect increases in parallel with GSH concentra-
of human GLO I-transfected CHO cells. Symbols are: () 1% FBS
tion. This finding suggests that GSH levels also are rateDMEM; ( ) medium with vector transfectant; () medium with GLO I
transfectant. A solution containing 100 mol/L of either GO or MGO limiting for GLO I activity. Still, they are compatible
was incubated with the culture supernatant obtained from human with a specific effect of GSH that might trap RCOs
GLO I-transfected (final GLO I activity 2.34 U/mL) or mock-trans-
through its thiol group; indeed, other thiol compoundsfected (final GLO I activity less than 0.01 U/mL) CHO cells for one
hour at 37C in the presence of various concentrations of GSH. GO, such as cysteine, or N-acetyl cysteine have a similar effect
or MGO levels were determined by HPLC. Reaction mixtures con- (data not shown). In contrast with RCO trapping agents
taining the culture medium (DMED with 1% FBS) without GSH were
such as aminoguanidine, which lower GO, MGO andused as controls. Data are expressed as percentage of each control and
represents the mean  SD of three independent experiments. *P  3-DG levels to a similar extent (from 85 to 50%) almost
0.005, **P  0.001. immediately, the effect of GLO I and GSH is more
selective.
Glutathione alone requires several hours to achieve a
maximal reduction of GO and MGO (90%), and a lessA and B lines of transgenic mice (data not shown). The
than 20% decrease of 3-DG levels. GLO I together withconcentrations of GO and MGO in the mixtures after a
GSH within a one hour incubation lower GO and MGOone hour incubation at 37C with tissue lysate of heart
levels by 90% both in solution or in PD fluid, but is lessfrom GLO I transgenic mice were significantly lower
(GO 59.1 mol/L; MGO 0.4 mol/L) than after incuba- efficient for 3-DG, which falls by less than 60% at a
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Fig. 5. Generation and characterization of
human GLO I transgenic mice. (A ) GLO I
transgene construct. Full-length human GLO I
cDNA was cloned in the rabbit -globin gene
including a part of the second intron, the third
exon, and the 3 untranslated region. The posi-
tions of primers (Pr1 and Pr2) for PCR analy-
sis are indicated above the construct. (B ) Im-
munoblot analysis of GLO I gene product.
Lane 1, 10% murine red blood cell suspension;
lane 2, 10% human red blood cell suspen-
sion; lane 3, kidney from wild-type mouse;
lanes 4 and 5, kidneys from F1 GLO I trans-
genic mice (lines A and B); lane 6, heart from
wild-type mouse; lanes 7 and 8, hearts from
F1 GLO I transgenic mice (lines A and B).
Table 1. GLO I activity in tissues of human GLO I transgenic mice
Heart Liver Kidney RBC Plasma
U/g mU/mL
GLO I Tg/ Line A 1096.2134.5 237.651.0 242.810.4 0.730.14 0.060.01
GLO I Tg/ Line B 719.455.3 241.061.6 84.034.3 0.660.15 0.490.22
Wild-type 20.14.1 169.552.1 37.22.4 0.690.07 0.050.05
GLO I activities in protein extracts of heart, liver, kidney, red blood cells, and plasma from human GLO I transgenic mice (lines A and B) or wild-type mice
were determined by the spectrophotometrical assay.
maximum concentration of GSH plus GLO I. The differ- trapping of pyridoxal, which when the compound is given
orally induces long-term severely disabling vitamin B6ence between the responses of the three tested RCOs is
most striking in the presence of overexpressed GLO I deficiency [24]. The fact that all RCOs are not reduced
in a similar fashion raises the problem of each RCO’sin the transfectant. MGO falls by more than 90%, GO
by approximately 40% and 3-DG by less than 20% at toxicity. In this context, it should be remembered that
only MGO (not GO or 3-DG) stimulated the productionthe highest GSH concentration. The difference is similar
in the presence GLO I overexpressed in organ extracts of of VEGF by endothelial and mesothelial cells in culture,
at least at concentrations above the physiological range.transgenic animals. This difference may reflect a variable
reactivity between the various RCOs and the SH group The possibility that each RCO has its own specific toxic-
ity remains to be investigated.of GSH illustrated in Figure 1. It is likely that this differ-
ence in reactivity is heightened in the GLO pathway The newer non-glucose PD solutions such as icodex-
trin and amino acid PD fluids have low levels of GO,since GLO I handles only the GSH-RCO complex. RCO
binding of GSH is a prerequisite for GLO I detoxifica- MGO, 3-DG as well as of total RCOs [12]. Similarly,
the multi-compartment bag system delivers a glucosetion, a characteristic accounting, at least in part, for the
selectivity of GLO I for RCO removal. PD solution with a very low RCO content and AGE
generation potential, despite conventional heat-steriliza-The therapeutic implications of RCO detoxification
in PD fluid by GLO I remain to be ascertained, as the tion and subsequent storage [25, 26]. Their clinical utility
has been recently assessed [27–29]. However, peritonealtested medium does not mirror the clinical situation. As
already pointed out, the selectivity of the GLO approach protein modifications result not only from RCOs present
in PD fluid but also from RCOs accumulating in uremicavoids one of the major limitations of RCO trapping
agents such as aminoguanidine or OPB-9195, that is, the blood [7]. With dwell time, total RCOs diffuse from
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RCOs such as GO or 3-DG, which were not raised by
hyperglycemia.
Our study not only demonstrates the beneficial effects
of GLO I added to peritoneal dialysis fluids, but also
provides, to our knowledge for the first time, the demon-
stration that genetically modified cells may augment
GLO I availability. To be practical, this latter approach
requires the development of an appropriate methodol-
ogy for increasing glyoxalase activity in vivo. Mesothe-
lium has been extensively used as a target for the overex-
pression of certain genes, for example, anti-inflammatory
and anti-oxidant enzymes [32]. Still, in vivo gene therapy
will have to overcome local changes resulting from in-
flammatory and immune responses and problems of gene
transfer efficiency, and regulation of transgene expres-
Fig. 6. Change in GO (A ) and MGO (B ) levels in tissues of human sion [33, 34].
GLO I transgenic mice. The heart tissue lysate from wild (final GLO I The clinical relevance and feasibility of our approachactivity 0.4 U/mL) and human GLO I transgenic mice, A line (final
remain to be tested. It is hoped that the increased GLO IGLO I activity 11.6 U/mL) were incubated with 100 mol/L of either
GO, or MGO for one hour at 37C in the presence of various concentra- expression generated in vivo in uremic subjects might
tions of GSH, followed by the determination of the GO or MGO lower circulating (and possibly intracellular) levels ofcontents by HPLC after derivatization to quinoxaline derivatives. Reac-
AGEs, a picture opposite to that recently described intion mixtures without GSH were used as control. Data are expressed
as the percentage of each control and represents the mean  SD of a GLO I-deficient patient [35].
three independent experiments. Symbols are: () heart tissue lysate
from wild-type mice; ( ) heart tissue lysate from human GLO I trans-
genic mice (A line). *P  0.05, **P  0.01. ACKNOWLEDGMENTS
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The RCO removal potential of overexpressed GLO I is
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